Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.38 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.38 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547440 | 1.00 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OGFRL1CCRL2 | |
| SCHEMBL20679665 | 1.00 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OGFRL1CCRL2 | |
| SCHEMBL18547273 | 0.92 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OGFRL1CCRL2 | |
| SCHEMBL20679656 | 0.92 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OGFRL1CCRL2 | |
| SCHEMBL18547274 | 0.92 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OGFRL1CCRL2 | |
| SCHEMBL18547256 | 0.84 | CNR1 (0.44) | OPRM1OPRD1OPRK1OGFRL1CACNB4 | |
| SCHEMBL20679672 | 0.84 | CNR1 (0.44) | OPRM1OPRD1OPRK1OGFRL1CACNB4 | |
| SCHEMBL18547257 | 0.84 | CNR1 (0.44) | OPRM1OPRD1OPRK1OGFRL1CACNB4 | |
| SCHEMBL18547774 | 0.84 | CNR1 (0.44) | OPRM1OPRD1OGFRL1KMT2ACNR1 | |
| SCHEMBL18547120 | 0.83 | CNR1 (0.39) | OPRM1OPRD1OPRK1OGFRL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | OPRM1 479/4885OPRD1 177/4885OPRK1 211/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | OPRM1 471/4885OPRD1 175/4885OPRK1 210/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | OPRM1 471/4885OPRD1 175/4885OPRK1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.